23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Structure Therapeutics Inc. › 2025-2026

Structure Therapeutics Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Structure Therapeutics Inc.’s Form 8-K, filed June 18, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 211Asset managers, any item
  • 906Fund votes
  • June 17, 2026Meeting date

Results at a glance

Meeting of June 17, 2026: 5 items on Structure Therapeutics Inc.’s Form 8-K, filed June 18, 2026: 2 approved · 3 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Structure Therapeutics Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Structure Therapeutics Inc.

These tallies are Structure Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Structure Therapeutics Inc. — official shareholder meeting results, meeting held June 17, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Ted W. Love, M.D. 164,241,780533,358172,641 --0 99.7%Passed (calculated)—
Elect Director: Raymond Stevens, Ph.D. 164,373,741400,929173,109 --0 99.8%Passed (calculated)—
Elect Director: Daniel G. Welch 161,336,0583,429,342182,379 --0 98%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Public Accounting Firm 164,767,21520,784159,780 --0 99.9%Approved—
Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Gen 158,547,4416,187,647212,691 --0 96%Approved—

Source: Structure Therapeutics Inc., Form 8-K, filed with the SEC on June 18, 2026 — read the filing on EDGAR.

How asset managers voted at the Structure Therapeutics Inc. 2025-2026 meeting

211 asset managers disclosed a vote on at least one Structure Therapeutics Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Daniel G. Welch

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 161,336,058AGAINST: 3,429,342
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Daniel G. Welch

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Daniel G. Welch”): 161,336,058 for, 3,429,342 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 19,574,137 for, 576,006 against, 10,973 abstained.

FOR
FOR: 19,574,137AGAINST: 576,006ABSTAIN: 10,973
Largest asset managers voting on “Election of the nominees for Class III director named below to hold office until the 2029 annual general meeti” at Structure Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,884,7300 00For
Vanguard3,486,4410 00For
JANUS INVESTMENT FUND1,588,2560 00For
T. Rowe Price1,563,0840 00For
American Century1,378,5530 00For
Principal1,221,00048,498 00For
PERMANENT PORTFOLIO FAMILY OF FUNDS750,0000 00For
Hartford452,6420 00For
BlackRock325,8670 00For
FRANKLIN STRATEGIC SERIES321,6470 00For
John Hancock270,0750 00For
DRIEHAUS MUTUAL FUNDS216,4840 00For
AllianceBernstein0212,692 00Against
AB DISCOVERY GROWTH FUND, INC.0161,888 00Against
Bridge Builder Trust147,7130 00For
Equitable31,60462,568 00Mixed
AIG/SunAmerica87,6430 00For
Lincoln Financial80,4970 00For
OPTIMUM FUND TRUST76,0150 00For
Delaware/Macquarie058,000 00Against
ALPS ETF Trust56,9110 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC49,5040 00For
Northwestern Mutual47,6540 00For
Allspring43,1710 00For
RBB FUND, INC.41,4030 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Elect Director: Raymond Stevens, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 164,373,741AGAINST: 400,929
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Raymond Stevens, Ph.D.

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Raymond Stevens, Ph.D.”): 164,373,741 for, 400,929 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 20,150,143 for, 10,973 abstained.

FOR
FOR: 20,150,143ABSTAIN: 10,973
Largest asset managers voting on “Election of the nominees for Class III director named below to hold office until the 2029 annual general meeti” at Structure Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,884,7300 00For
Vanguard3,486,4410 00For
JANUS INVESTMENT FUND1,588,2560 00For
T. Rowe Price1,563,0840 00For
American Century1,378,5530 00For
Principal1,269,4980 00For
PERMANENT PORTFOLIO FAMILY OF FUNDS750,0000 00For
Hartford452,6420 00For
BlackRock325,8670 00For
FRANKLIN STRATEGIC SERIES321,6470 00For
John Hancock270,0750 00For
DRIEHAUS MUTUAL FUNDS216,4840 00For
AllianceBernstein212,6920 00For
AB DISCOVERY GROWTH FUND, INC.161,8880 00For
Bridge Builder Trust147,7130 00For
Equitable94,1720 00For
AIG/SunAmerica87,6430 00For
Lincoln Financial80,4970 00For
OPTIMUM FUND TRUST76,0150 00For
Delaware/Macquarie58,0000 00For
ALPS ETF Trust56,9110 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC49,5040 00For
Northwestern Mutual47,6540 00For
Allspring43,1710 00For
RBB FUND, INC.41,4030 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Elect Director: Ted W. Love, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 164,241,780AGAINST: 533,358
Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: Election of the nominees for Class III director named below to hold office until the 2029 annual general meeting of shareholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Ted W. Love, M.D.

Structure Therapeutics Inc.’s own tally for this item (“Elect Director: Ted W. Love, M.D.”): 164,241,780 for, 533,358 against, per its Form 8-K filed June 18, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 20,150,143 for, 10,973 abstained.

FOR
FOR: 20,150,143ABSTAIN: 10,973
Largest asset managers voting on “Election of the nominees for Class III director named below to hold office until the 2029 annual general meeti” at Structure Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,884,7300 00For
Vanguard3,486,4410 00For
JANUS INVESTMENT FUND1,588,2560 00For
T. Rowe Price1,563,0840 00For
American Century1,378,5530 00For
Principal1,269,4980 00For
PERMANENT PORTFOLIO FAMILY OF FUNDS750,0000 00For
Hartford452,6420 00For
BlackRock325,8670 00For
FRANKLIN STRATEGIC SERIES321,6470 00For
John Hancock270,0750 00For
DRIEHAUS MUTUAL FUNDS216,4840 00For
AllianceBernstein212,6920 00For
AB DISCOVERY GROWTH FUND, INC.161,8880 00For
Bridge Builder Trust147,7130 00For
Equitable94,1720 00For
AIG/SunAmerica87,6430 00For
Lincoln Financial80,4970 00For
OPTIMUM FUND TRUST76,0150 00For
Delaware/Macquarie58,0000 00For
ALPS ETF Trust56,9110 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC49,5040 00For
Northwestern Mutual47,6540 00For
Allspring43,1710 00For
RBB FUND, INC.41,4030 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 158,547,441AGAINST: 6,187,647

Prior year: 85.7% for (June 23, 2025 meeting) ▲ 10.6 pts

Details: description as filed, official tally, votes by 211 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Structure Therapeutics Inc.’s own tally for this item (“Proposal 3: Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Comp”): 158,547,441 for, 6,187,647 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory vote on the compensation of the Company's named executive officers On an advisory basis, the shareholders approved the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual General Meeting.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at Structure Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,884,7300 00For
Vanguard3,486,4410 00For
JANUS INVESTMENT FUND1,588,2560 00For
T. Rowe Price1,563,0840 00For
American Century01,378,553 00Against
Principal1,269,4980 00For
PERMANENT PORTFOLIO FAMILY OF FUNDS750,0000 00For
Hartford452,6420 00For
BlackRock325,8670 00For
FRANKLIN STRATEGIC SERIES321,6470 00For
John Hancock270,0750 00For
DRIEHAUS MUTUAL FUNDS216,4840 00For
AllianceBernstein212,6920 00For
AB DISCOVERY GROWTH FUND, INC.161,8880 00For
Bridge Builder Trust147,7130 00For
Equitable94,1720 00For
AIG/SunAmerica87,6430 00For
Lincoln Financial080,497 00Against
OPTIMUM FUND TRUST76,0150 00For
Delaware/Macquarie58,0000 00For
ALPS ETF Trust56,9110 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC49,5040 00For
Northwestern Mutual47,6540 00For
Allspring43,1710 00For
RBB FUND, INC.41,4030 00For

Fund voting reports, all 56 managers: 18,690,732 for, 1,459,411 against, 10,973 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 167 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at Structure Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson10,284,4050 00For
Fidelity8,030,0400 00For
Wellington6,361,5180 00For
Avoro Capital Advisors LLC5,140,7240 00For
Deep Track Capital, LP4,079,8480 00For
BVF INC/IL3,459,3580 00For
T. Rowe Price1,968,1400 00For
American Century01,532,178 00Against
PRINCIPAL GLOBAL INVESTORS1,521,5680 00For
ORBIMED ADVISORS LLC1,475,4030 00For
Siren, L.L.C.1,293,4230 00For
DRIEHAUS CAPITAL MANAGEMENT LLC1,053,0470 00For
Casdin Capital, LLC906,3630 00For
DEERFIELD MANAGEMENT COMPANY, L.P.874,0000 00For
Logos Global Management LP787,0680 00For
Paradigm Biocapital Advisors LP734,5220 00For
AllianceBernstein674,8770 00For
Rock Springs Capital Management LP640,2300 00For
FRANKLIN ADVISERS INC571,7100 00For
Aberdeen391,8090 00For
Catalio Capital Management, LP249,5870 00For
AMERIPRISE FINANCIAL INC214,8980 00For
OAK RIDGE INVESTMENTS LLC206,1690 00For
Pentwater Capital Management LP206,1690 00For
Eversept Partners, LP167,6190 00For

Institutional-manager reports, all 167 managers: 53,494,354 for, 1,717,681 against, 196 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 164,767,215AGAINST: 20,784

Prior year: 100.0% for (June 23, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 56 asset managers

Description as filed by funds: To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Structure Therapeutics Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 164,767,215 for, 20,784 against — passed, per its Form 8-K filed June 18, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's shareholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 20,150,143 for, 10,973 abstained.

FOR
FOR: 20,150,143ABSTAIN: 10,973
Largest asset managers voting on “To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company” at Structure Therapeutics Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity6,884,7300 00For
Vanguard3,486,4410 00For
JANUS INVESTMENT FUND1,588,2560 00For
T. Rowe Price1,563,0840 00For
American Century1,378,5530 00For
Principal1,269,4980 00For
PERMANENT PORTFOLIO FAMILY OF FUNDS750,0000 00For
Hartford452,6420 00For
BlackRock325,8670 00For
FRANKLIN STRATEGIC SERIES321,6470 00For
John Hancock270,0750 00For
DRIEHAUS MUTUAL FUNDS216,4840 00For
AllianceBernstein212,6920 00For
AB DISCOVERY GROWTH FUND, INC.161,8880 00For
Bridge Builder Trust147,7130 00For
Equitable94,1720 00For
AIG/SunAmerica87,6430 00For
Lincoln Financial80,4970 00For
OPTIMUM FUND TRUST76,0150 00For
Delaware/Macquarie58,0000 00For
ALPS ETF Trust56,9110 00For
PRINCIPAL VARIABLE CONTRACTS FUNDS INC49,5040 00For
Northwestern Mutual47,6540 00For
Allspring43,1710 00For
RBB FUND, INC.41,4030 00For

Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).

Largest Structure Therapeutics Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 213,208,000 shares outstanding at the time of that meeting.

Fund voting reports: top Structure Therapeutics Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 3.23%
2Vanguard 1.64%
3JANUS INVESTMENT FUND 0.74%
4T. Rowe Price 0.73%
5American Century 0.65%
6Principal 0.60%
7PERMANENT PORTFOLIO FAMILY OF FUNDS 0.35%
8Hartford 0.21%
9BlackRock 0.15%
10FRANKLIN STRATEGIC SERIES 0.15%
Institutional-manager reports: top Structure Therapeutics Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 4.82%
2Fidelity 3.77%
3Wellington 2.98%
4Avoro Capital Advisors LLC 2.41%
5Deep Track Capital, LP 1.91%
6BVF INC/IL 1.62%
7T. Rowe Price 0.92%
8American Century 0.72%
9PRINCIPAL GLOBAL INVESTORS 0.71%
10ORBIMED ADVISORS LLC 0.69%

Reported Structure Therapeutics Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Structure Therapeutics Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with FMR LLC31,112,634 14.59%Proxy statement (DEF 14A), proxy filed April 23, 2026
Entities affiliated with Wellington Management Group LLP21,365,952 10.02%Proxy statement (DEF 14A), proxy filed April 23, 2026
Entities affiliated with Avoro Capital Advisors LLC20,832,051 9.77%Proxy statement (DEF 14A), proxy filed April 23, 2026
Entities affiliated with Janus Henderson Group plc13,346,478 6.26%Proxy statement (DEF 14A), proxy filed April 23, 2026
Deep Track Capital, LP12,335,346 5.79%Schedule 13G, filed February 13, 2026
Entities affiliated with Deep Track Capital, LP12,335,346 5.79%Proxy statement (DEF 14A), proxy filed April 23, 2026
BVF PARTNERS L P/IL10,437,066 4.90%Schedule 13G, filed February 17, 2026
FMR (Fidelity)8,403,449 3.94%Form 13F, quarter ended March 31, 2026
Wellington Management7,260,287 3.41%Form 13F, quarter ended March 31, 2026
Raymond Stevens, Ph.D.4,615,182 2.16%Proxy statement (DEF 14A), proxy filed April 23, 2026

Percentages above are of 213,208,000 shares outstanding, as reported by Structure Therapeutics Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Structure Therapeutics Inc.'s shareholder meeting held June 17, 2026, in the 2025-2026 proxy season, 211 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 906 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — Structure Therapeutics Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Structure Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Structure Therapeutics Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Structure Therapeutics Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Structure Therapeutics (GPCR) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/structure-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.